Cancer-on-a-chip pioneer Chen Weiqiang leaves NYU for Nanjing University
Synopsis
Tenured NYU professor and cancer-on-a-chip specialist Chen Weiqiang has left New York University to join Nanjing University as a distinguished professor — explicitly stating the move was personal, not political, even as US-China science tensions intensify.
Key Takeaways
Chen Weiqiang , a tenured professor at NYU Tandon School of Engineering , joined Nanjing University as a distinguished professor in biomedical engineering.
A welcome ceremony was held at Nanjing University's Suzhou campus on June 11, 2026 .
Chen said he completed his work at NYU in May 2026 and explicitly stated his return was driven by "personal career development and family reasons," not US political changes.
Chen earned his bachelor's degree from Nanjing University in 2005 and a master's from Shanghai Jiao Tong University in 2008 .
His research focus — cellular biomechanics and organ-on-a-chip systems — is a strategic biomedical priority receiving significant institutional investment in China .
Chen Weiqiang, a tenured professor of mechanical and biomedical engineering at New York University (NYU) and a leading researcher in cancer-on-a-chip technology, has joined Nanjing University as a distinguished professor in its school of biomedical engineering. The move, confirmed at a welcome ceremony held at Nanjing University's Suzhou campus on June 11, 2026, marks a significant return of high-calibre scientific talent to China.
A high-profile homecoming
Nanjing University assistant president Jiang Tian introduced Chen at the ceremony, describing him as deeply embedded in top overseas institutions and credited with "remarkable results in cutting-edge fields such as cellular biomechanics and organ chips." Jiang noted that Chen "chose to join Nanjing University during his peak academic years," calling the decision "truly moving." Prior to the move, Chen served as a professor and director of graduate education at the NYU Tandon School of Engineering.
Why he returned — in his own words
Chen addressed the motivations behind his decision directly. "In May, I finished my work at New York University and returned to China to work," he said. "My decision to come back was primarily based on personal career development and family reasons, and I did not take into account the political changes in the United States." The statement is notable given the current climate of US-China tensions in science and technology, though Chen explicitly distanced his choice from geopolitical factors.
Academic roots and research focus
Chen's academic journey began at Nanjing University, where he earned a bachelor's degree from the physics school in 2005. He subsequently obtained a master's degree in electrical engineering from Shanghai Jiao Tong University in 2008. His research spans cellular biomechanics and organ-on-a-chip systems — micro-engineered platforms that replicate human organ functions, with applications in cancer diagnostics and drug testing. These technologies sit at the intersection of microfluidics, bioengineering, and oncology, representing one of the most competitive frontiers in biomedical science globally.
The competitive backdrop
Chen's return is part of a broader pattern of Chinese universities recruiting overseas-based scientists, particularly as US funding constraints and visa uncertainties have created friction for researchers of Chinese origin working in America. Nanjing University and peer institutions have aggressively expanded distinguished professor programmes to attract talent with established international track records. The organ-chip sector, in particular, has drawn significant state and institutional investment in China as a strategic biomedical priority.
What's next
Chen's integration into Nanjing University's biomedical engineering school is expected to accelerate the institution's organ-chip research capabilities. Observers will watch whether his lab attracts further international collaborations or becomes a hub for domestic talent development — and whether his case signals an accelerating trend of mid-career scientists making similar transitions.
Point of View
Tenured scientist at a top American engineering school choosing to relocate is precisely the profile that US science policy was supposed to retain. What mainstream coverage underplays is the institutional pull side — Chinese universities are not merely waiting for disaffected researchers; they are running sophisticated, well-funded recruitment pipelines targeting scientists at exactly Chen's career stage, when their networks and methodologies are most productive. The organ-chip sector is also strategically significant: it underpins next-generation drug discovery and personalised oncology, areas where China is racing to reduce dependence on Western pharmaceutical pipelines.
NationPress
21 Jun 2026
Frequently Asked Questions
Who is Chen Weiqiang and why is his move significant?
Chen Weiqiang is a tenured professor of mechanical and biomedical engineering at New York University and a specialist in cancer-on-a-chip and cellular biomechanics research. His move to Nanjing University is significant because he was a tenured, mid-career professor at a leading US institution — the profile of researcher that is hardest to replace and most valuable to recruit.
Why did Chen Weiqiang leave NYU for China?
Chen stated that his decision was "primarily based on personal career development and family reasons" and that he "did not take into account the political changes in the United States ." He completed his work at NYU in May 2026 before returning to China .
What is cancer-on-a-chip technology?
Cancer-on-a-chip, a subset of organ-on-a-chip technology, refers to micro-engineered devices that replicate the biological environment of human tumours or organs on a small chip. These platforms are used to study cancer behaviour and test drug responses outside the human body, offering faster and more accurate results than traditional cell cultures.
What role will Chen Weiqiang have at Nanjing University?
Chen Weiqiang has joined Nanjing University's school of biomedical engineering as a distinguished professor. A formal welcome ceremony was held at the university's Suzhou campus on June 11, 2026 .
Is Chen Weiqiang's return part of a larger trend?
Yes. Chen's return reflects a broader pattern of Chinese universities actively recruiting overseas-based scientists, particularly amid US funding pressures and visa uncertainties affecting researchers of Chinese origin. Institutions like Nanjing University have expanded distinguished professor programmes specifically targeting mid-career scientists with strong international track records.
